Bam, Nokwanda E.; Mabunda, Sikhumbuzo A.; Ntsaba, Jafta; Apalata, Teke; Nomatshila, Sibusiso C.; Chitha, Wezile published the artcile< The association between HIV tri-therapy with the development of Type-2 Diabetes Mellitus in a rural South African District: A case-control study>, SDS of cas: 112-63-0, the main research area is HIV infection type2 DM antiretroviral drug stavudine zidovudine lopivavir.
We sought to confirm the association of cARVs with type-2 DM and ascertain the extent of this association in a rural South African setting. Methods: A case-control study of 177 (33.33%) cases with HIV/AIDS and type-2 DM were selected and compared with 354 (66.67%) non-DM HIV/AIDS unmatched controls from a rural district of South Africa’s third most populous province (Eastern Cape). Odds Ratios (OR), together with 95% confidence intervals, were calculated for all the univariable and multivariable logistic analyses. Results: This study found that cARVs significantly increased the occurrence of type-2 DM among HIV patients. Patients on protease inhibitors (PIs) were at least 21 times significantly (p<0.0001) more likely to be diabetic than those on the fixed dose combination (FDC); those on stavudine (D4T) and zidovudine (AZT) were 2.45 times and 9.44 times resp. more likely to be diabetic than those on FDC (p<0.05). The odds of diabetes increased by more than three-folds for those who had been on antiretroviral drugs for more than 6 years (p<0.005). Conclusion: This study has been able to establish the association between cARVs and type-2 DM. It therefore proposes consideration of the usage of AZT, D4T, lopivavir and ritonavir for the treatment of HIV. The study further proposes more prospective research to test these findings further. PLoS One published new progress about Antiviral agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, SDS of cas: 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics